Tiger Brokers

BUZZ-CERo climbs after blood cancer drug trial moves to next phase

Reuters
Oct 13
BUZZ-CERo climbs after blood cancer drug trial moves to next phase

** U.S. drug developer CERo Therapeutics' CERO.O shares rise 7.2% to $3.55 in premarket trade

** Co says its experimental drug for a type of blood drug, CER-1236 cleared a key safety milestone, allowing higher dosing in its ongoing clinical trial

** CERO's CER-1236 is being tested in patients with acute myeloid leukemia, a fast-growing cancer of the blood and bone marrow

** CERO says no serious side effects in initial patient group, clears path for higher dose

** Safety panel clears start of second cohort with higher initial dose - CERO

** CERO says it is not for sale, correcting recent media report

** Co says focus remains on dose escalation trial, not seeking partnerships

** Up to last close, stock down ~97% YTD

(Reporting by Sahil Pandey)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10